It is a privilege to be able to contribute to this volume in which Professor Zervas’ friends, students, and colleagues have joined together to honor him and his remarkable contributions to peptide chemistry. Although I did not know him until after his days in the Bergmann Laboratory at the Rockefeller Institute, I can claim the distinction of now working in those very same rooms that they occupied back in the mid-1930s. Like all peptide chemists, I am greatly indebted to Professor Zervas, having depended so heavily on the carbobenzoxy group and on the various modified urethan protecting groups which have been direct extensions of the revolutionary advance that Bergmann and Zervas made.

Solid-phase peptide synthesis.

Safety assessment of butylated hydroxyanisole and butylated hydroxytoluene as antioxidant food additives.

Genotoxicity testing aims to detect a large range of genetic damage endpoints and evaluate such results in context of cell survival. The cytokinesis block micronucleus test offers the advantage to provide simultaneously information on both cell cycle progression and chromosome/genome mutations. Indeed, 1. frequencies of cytokinesis-blocked binucleated cells (and polynucleated) are good estimators of the mitotic rate; 2. frequencies of apoptotic figures in mononucleated and binucleated cells provide a measure for cell death before or after cell division; 3. combination of fluorescence in situ hybridization (FISH) for centromere/telomeres and micronucleus scoring allows discrimination between clastogenic and aneugenic events; 4. detection of FISH signals for chromosome specific sequences in both macronuclei and micronuclei, discriminates between aneuploidy due to chromosome non-disjunction or to chromosome loss. The cytokinesis block in vitro micronucleus test is thus a cytogenetic multi-test providing mechanistic information with a simple, rapid, objective, microscopical analysis.

The in vitro micronucleus test: a multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction.

An expert working group on the in vivo micronucleus assay, formed as part of the International Workshop on Genotoxicity Test Procedures (IWGTP), discussed protocols for the conduct of established and proposed micronucleus assays at a meeting held March 25-26, 1999 in Washington, DC, in conjunction with the annual meeting of the Environmental Mutagen Society. The working group reached consensus on a number issues, including: (1) protocols using repeated dosing in mice and rats; (2) integration of the (rodent erythrocyte) micronucleus assay into general toxicology studies; (3) the possible omission of concurrently-treated positive control animals from the assay; (4) automation of micronucleus scoring by flow cytometry or image analysis; (5) criteria for regulatory acceptance; (6) detection of aneuploidy induction in the micronucleus assay; and (7) micronucleus assays in tissues (germ cells, other organs, neonatal tissue) other than bone marrow. This report summarizes the discussions and recommendations of this working group. In the classic rodent erythrocyte assay, treatment schedules using repeated dosing of mice or rats, and integration of assays using such schedules into short-term toxicology studies, were considered acceptable as long as certain study criteria were met. When the micronucleus assay is integrated into ongoing toxicology studies, relatively short-term repeated-dose studies should be used preferentially because there is not yet sufficient data to demonstrate that conservative dose selection in longer term studies (longer than 1 month) does not reduce the sensitivity of the assay. Additional validation data are needed to resolve this point. In studies with mice, either bone marrow or blood was considered acceptable as the tissue for assessing micronucleus induction, provided that the absence of spleen function has been verified in the animal strains used. In studies with rats, the principal endpoint should be the frequency of micronucleated immature erythrocytes in bone marrow, although scoring of peripheral blood samples gives important supplementary data about the time course of micronucleus induction. When dose concentration and stability are verified appropriately, concurrent treatment with a positive control agent is not necessary. Control of staining and scoring procedures can be obtained by including appropriate reference samples that have been obtained from a separate experiment. For studies in rats or mice, treatment/sampling regimens should include treatment at intervals of no more than 24 hr (unless the test article has a half-life of more than 24 hr) with sampling of bone marrow or blood, respectively, within 24 or 40 hr after the last treatment. The use of a DNA specific stain is recommended for the identification of micronuclei, especially for studies in the rat. In the case of a negative assay result with a non-toxic test article, it is desirable that systemic exposure to the test article is demonstrated. The group concluded that successful application of automated scoring by both flow cytometry and image analysis had been achieved, and defined criteria that should be met if automated scoring is employed. It was not felt appropriate to attempt to define specific recommended protocols for automated scoring at the present time. Other issues reviewed and discussed by the working group included micronucleus assays that have been developed in a number of tissues other than bone marrow. The group felt that these assays were useful research tools that could also be used to elucidate mechanisms in certain regulatory situations, but that these assays had not yet been standardized and validated for routine regulatory application.

In vivo rodent erythrocyte micronucleus assay. II. Some aspects of protocol design including repeated treatments, integration with toxicity testing, and automated scoring.

BHT is the recognized name in the cosmetics industry for butylated hydroxytoluene. BHT is used in a wide range of cosmetic formulations as an antioxidant at concentrations from 0.0002% to 0.5%. BHT does penetrate the skin, but the relatively low amount absorbed remains primarily in the skin. Oral studies demonstrate that BHT is metabolized. The major metabolites appear as the carboxylic acid of BHT and its glucuronide in urine. At acute doses of 0.5 to 1.0 g/kg, some renal and hepatic damage was seen in male rats. Short-term repeated exposure to comparable doses produced hepatic toxic effects in male and female rats. Subchronic feeding and intraperitoneal studies in rats with BHT at lower doses produced increased liver weight, and decreased activity of several hepatic enzymes. In addition to liver and kidney effects, BHT applied to the skin was associated with toxic effects in lung tissue. BHT was not a reproductive or developmental toxin in animals. BHT has been found to enhance and to inhibit the humoral immune response in animals. BHT itself was not generally considered genotoxic, although it did modify the genotoxicity of other agents. BHT has been associated with hepatocellular and pulmonary adenomas in animals, but was not considered carcinogenic and actually was associated with a decreased incidence of neoplasms. BHT has been shown to have tumor promotion effects, to be anticarcinogenic, and to have no effect on other carcinogenic agents, depending on the target organ, exposure parameters, the carcinogen, and the animal tested. Various mechanism studies suggested that BHT toxicity is related to an electrophillic metabolite. In a predictive clinical test, 100% BHT was a mild irritant and a moderate sensitizer. In provocative skin tests, BHT (in the 1% to 2% concentration range) produced positive reactions in a small number of patients. Clinical testing did not find any depigmentation associated with dermal exposure to BHT, although a few case reports of depigmentation were found. The Cosmetic Ingredient Review Expert Panel recognized that oral exposure to BHT was associated with toxic effects in some studies and was negative in others. BHT applied to the skin, however, appears to remain in the skin or pass through only slowly and does not produce systemic exposures to BHT or its metabolites seen with oral exposures. Although there were only limited studies that evaluated the effect of BHT on the skin, the available studies, along with the case literature, demonstrate no significant irritation, sensitization, or photosensitization. Recognizing the low concentration at which this ingredient is currently used in cosmetic formulations, it was concluded that BHT is safe as used in cosmetic formulations.

Final report on the safety assessment of BHT(1).

Micronucleated cells (MN cells) are present in the blood as rare events (i.e. about 2 MN cells/1000 total). Scoring MN cells by hand is both time-consuming and tedious, which is the primary reason why only 1000–2000 total cells (PCEs) are routinely scored for each sample. It is generally recognized that scoring larger numbers of cells would improve assay statistics and is desirable, but impractical with hand-scoring. In contrast, automated scoring methods can process large numbers of cells, thus improving statistical analysis. In order to accurately and quickly evaluate clastogenic activity, we have developed a flow cytometry based method of scoring micronucleated cells. One of the first steps in developing an automated assay is to demonstrate the ability of the method to resolve the cells of interest. In this case, micronucleated cells must be resolved from DNA-deficient red blood cells (RBCs). Since micronuclei are heterogeneous rare events which vary in both size and DNA content, we chose to use a more enriched and homogeneous biological model for optimizing the experimental variables of this assay, leading to high resolution of the rare cells. Experiments are described in which the murine malaria parasite, P. berghei, served as a micronucleus model and facilitated the development of an accurate flow cytometry based scoring method. This parasite resides in the red blood cell population and endows the cells with a homogeneous (genetically determined) DNA component in the micronucleus size range. The conditions developed with the malaria parasite are readily applied to the analysis of micronucleus events in blood samples. Bivariate profiles that are obtained with the malaria parasite can be used to define the analysis area for high-speed micronucleus scoring.

Analysis of micronucleated cells by flow cytometry. 1. Achieving high resolution with a malaria model

Micronucleated cells (MN cells) generated spontaneously or by clastogen action accumulate in the peripheral blood of the mouse, and their presence reflects the level of chromosome damage. Traditionally, micronucleated cells have been scored by visual inspection. With the development of flow cytometry based scoring procedures, vast numbers of cells can be analyzed, making it possible to determine the change in the number of MN cells in the total peripheral blood pool. This report describes experiments whereby initial blood samples were obtained before dosing, providing mouse-specific controls for measuring subsequent changes in MN cells. Mice were then dosed with saline (solvent control), methyl methanesulfonate, cyclophosphamide or colchicine every 48 h and bled every 96 h for 12 days. For each blood sample, one million fixed erythrocytes (RBCs) were interrogated for the presence of micronuclei, and regression analysis was used to determine the rate of MN cell influx per day for each animal or sets of animals. To evaluate the effect of treatment on MN induction, the mean slopes of solvent and chemically treated animals were compared using t-tests. The results of these experiments indicate that the kinetics of MN induction continues near the background frequency for saline dosed mice, whereas clastogenic agents or spindle poisons cause a significant influx of MN events into the blood. The results suggest that some studies may benefit from a flow cytometry based analysis of multiple blood samples, especially when the number of mice is limited, or when a weak clastogen is being investigated.

Analysis of micronucleated cells by flow cytometry. 4. Kinetic analysis of cytogenetic damage in blood.

Under optimum conditions, flow cytometry (FCM) can provide a powerful technology for analyzing rare micronucleated cells in the peripheral blood. Our efforts in this endeavor have been directed toward a careful and meticulous optimization of experimental conditions, in order to achieve high resolution and high accuracy before introducing biological variation. We have achieved high resolution (Tometsko et al., 1993a) wherein the micronucleus signal is moved 100-fold upfield and away from the DNA deficient red blood cell (RBC) peak. In addition, we have demonstrated the high accuracy of our flow cytometry method in scoring rare micronucleated cells (Tometsko et al., 1993b). In the course of our studies, we rigorously pursued conditions which minimized experimental noise, demanding that FCM-scoring accuracy should approach theoretical limits. Thus, we laid the foundation for detecting clastogen activity with great sensitivity. The experiments described herein extend the previous studies by using high-speed flow cytometry to detect a clastogen-induced increase in MN cells in the total erythrocyte population. Methyl methanesulfonate (MMS) served as a model clastogen in these studies. This manuscript describes our development of a suitable blood-sampling regimen, the advantages of obtaining initial blood samples before dosing, the sex-linked difference in background micronucleus levels in BALB/c mice, and the analysis of a clastogen-induced biological response in male and female mice. As described, our flow cytometry method is able to provide a quantitative analysis of the net change in micronucleated cells (ΔMN) for each mouse.

analysis of micronucleated cells by flow cytometry. 3. Advanced technology for detecting clastogenic activity

Micronucleated blood cells — whether generated spontaneously or by clastogen treatment — are present in the blood and bone marrow as rare events. Historically they have been scored manually by microscopic inspection which is labor-intensive and tedious. It has been recognized by investigators that a need exists for an automated method which can accurately, objectively and quantitatively score rare micronucleated cells. In order to improve assay statistics more cells must be processed, making high-speed scoring an important objective of any automated procedure. Flow cytometry can provide the means to quantitatively analyze micronucleated cells at high speeds and with great accuracy once the chemical, biological and instrumentation conditions are optimized. Recent literature suggests that noise and fidelity of the data, as well as the sensitivity of present flow cytometers, are major obstacles that still must be overcome. Experiments are described herein which demonstrate that flow cytometry is able to score micronucleated cells under conditions where noise levels are low, and the fidelity and accuracy are high. In addition, the accuracy of scoring rare events is maintained at high speeds (e.g. 1 000 000 cells/min). A major emphasis of this manuscript is to demonstrate the means for evaluating the accuracy and sensitivity of the flow cytometer in scoring rare events. Both computer simulation and reconstruction experiments were used to gauge scoring accuracy and guided optimization experiments. These experiments demonstrate that when optimum conditions are used in conjunction with a suitable flow cytometer, it is possible to score micronucleated cells at high speeds with great precision.

Analysis of micronucleated cells by flow cytometry. 2. Evaluating the accuracy of high-speed scoring.

Genotoxic chemicals are an existing wide-spread health hazard to the human population. Advances in genetic toxicology testing have made it possible to assay potential mutagens, carcinogens, teratogens and clastogens in the environment. The mouse micronucleus assay provides an example of an excellent test for genetic damage to cells. When chromosome breaks occur in the blood stem cell population, the damaged piece of chromosome remains behind as a micronucleus in the normally DNA deficient red blood cells. However, currently available manual micronucleus assays are costly, time consuming, and labor intensive. In addition, the statistics are often marginal since the number of micronucleii (MNs) in 1000 polychromatic cells are scored manually, yielding limited amounts of data. This invention discloses the means for assaying the change in micronucleated cells by high speed flow cytometry. In this procedure, cells are streamed at high speed (2500 cells/second) through a laser beam whereupon the fluorescence emission and light scatter properties of each cell are obtained. The invention discloses the procedures for dosing mice, obtaining blood samples, fixing and staining cells, configuring the flow cytometer for MN analysis, the mode of data acquistion and analysis. Internal and external quality controls are also described that are routinely used to optimize the flow cytometer conditions and permit the evaluation of the fidelity of data in real time. This process permits the analysis of 1,000,000 total cells for each sample in minutes, and it removes the subjective judgement of the manual method. In addition to vastly improved statistics, the sensitivity of the assay is significantly improved with this process.

Andrew M. Tometsko

Papers

Analysis of micronucleated cells by flow cytometry. 1. Achieving high resolution with a malaria model

Analysis of micronucleated cells by flow cytometry. 4. Kinetic analysis of cytogenetic damage in blood.

analysis of micronucleated cells by flow cytometry. 3. Advanced technology for detecting clastogenic activity

Analysis of micronucleated cells by flow cytometry. 2. Evaluating the accuracy of high-speed scoring.

Process for analyzing clastogenic agents